| |
|
|
|
Seaport Hotel, Boston, MA
September 23-24, 2013
Monday, September 23: CURRENT OPTIONS AND CONSIDERATIONS FOR PREGNANCY RISK ASSESSMENT - Prenatal Genetic Diagnosis: Balancing the Options
- Medical Decision-Making Models in Prenatal Diagnostics
- Reimbursement Issues for Prenatal Diagnostics: How Do the Payers Look at This Field
- How the Changing Patent Landscape Will Impact the Future of Prenatal Molecular Diagnostics
- How Has the Integration of Non-Invasive Prenatal Testing Changed Current Standard of Care, and What's Next?
ARRAY-BASED CYTOGENETIC TESTING - Array CGH vs. Classical Cytogenetics in Prenatal Diagnostics
- High Density SNP Arrays for Prenatal Cytogenetic Analysis
- Clinical Validation of Prenatal Microarrays in Prospective High-Risk Pregnancies
- Panel Discussion: Sequencing-Based Diagnostics of Cell-Free DNA in Maternal Blood
Tuesday, September 24: ADVANCES IN ISOLATION AND ANALYSIS OF FETAL CELLS - Thinking about Selecting between Cell-Free and Fetal Cell Analysis, Now and in the Future
- Options for Analysis of Single Fetal Cells
- Life at the Single Molecule Level: Single Cell Genomics
- CGH Microarray Analysis of Fetal Cells Isolated from Maternal Blood
- Non-Invasive Prenatal Diagnosis through Genetic Analysis of Trophoblastic Cells, Isolated by ISET
- A Workflow for the Isolation and Molecular Characterization of Individual Circulating Fetal Cells in Non-Invasive Prenatal Diagnosis
BIOMARKERS FOR EARLIER ASSESSMENT OF PREGNANCY COMPLICATIONS: PREECLAMPSIA - Highly Sensitive and Specific Serum Test for Risk of Preeclampsia
- First Trimester Screening for Early Onset Preeclampsia
- Triaging First-Time Pregnant Women into Different Strata of Personalized Prenatal Care - The Preeclampsia Case
BIOMARKERS FOR EARLIER ASSESSMENT OF PREGNANCY COMPLICATIONS: PRE-TERM LABOR - Strategies towards Non-Invasive Prediction of Preterm Birth and Prenatal Diagnosis
- Serum-Based Exosomal Multiplexed Protein Assay for Pre-Term Birth
- Closing Panel Discussion: What Will the Prenatal Molecular Diagnostic Landscape Look Like in 3-5 Years?
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- Ronald J. Wapner, M.D., Director, Reproductive Genetics; Vice Chair of Research, Department of Obstetrics and Gynecology, Columbia University Medical Center
- Kee Chan, Ph.D., Department of Health Sciences, Boston University
- Robert C. McDonald, M.D., MBA, President, Aledo Consulting
- Tara Rachinsky, Ph.D., Counsel, Intellectual Property, Fox Rothschild LLP
- Diana W. Bianchi, M.D., Executive Director, Mother Infant Research Institute; Professor of Pediatrics, Obstetrics and Gynecology, Tufts University School of Medicine
- Ankita Patel, Ph.D., Department of Molecular and Human Genetics, Baylor College of Medicine
- Stuart Schwartz, Ph.D., FACMG, Strategic Director, Cytogenetics, Laboratory Corporation of America
- M. Anwar Iqbal, Ph.D., Director, Cytogenetics and Microarray CGH Lab, Department of Pathology and Laboratory Medicine, University of Rochester and Medical Center
- Sucheta Bhatt, M.D., Director of Genetics, Verinata Health, Inc.
- Mathias Ehrich, Ph.D., Vice President of Research & Development, Sequenom, Inc.
- Thomas Musci, M.D., Vice President, Clinical and Medical Affairs, Ariosa Diagnostics, Inc.
- Zach Demko, Ph.D., Senior Director of Research & Development, Natera, Inc.
- Joe Leigh Simpson, M.D., Senior Vice President, Research and Global Programs, March of Dimes Foundation
- Arthur Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine
- Xiaoliang (Sunney) Xie, Ph.D., Department of Chemistry and Chemical Biology, Harvard University
- Bhairavi Parikh, PhD, CEO and Co-Founder, CellScape Corp.
- Prof. Patrizia Paterlini-Brechot, Ph.D., Chief Scientific Officer, RareCells, and Department of Cell Biology & Oncology, University Paris Descartes
- Francesca Fontana, Ph.D., R&D Biology Project Leader, Silicon Biosystems S.p.A.
- Matthew Cooper, Ph.D., CEO, Carmenta Biosciences
- Garrett Lam, M.D., Assistant Director and Assistant Professor, Ob/Gyn Division of Maternal Fetal Medicine, Regional Obstetrical Consultants and University Of Tennessee, Chattanooga
- Robyn Tuytten, Ph.D., Vice President, Research & Development, Metabolomic Diagnostics Ltd.
- Farideh Bischoff, Ph.D., Scientific Advisor, KellBenx, Inc.
- Alan Ezrin, Ph.D., President & CEO, NX PharmaGen
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
August 23, 2013
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|